Literature DB >> 15597250

[Cost-of-illness Study for the Treatment of COPD in Germany].

D Nowak1, E S Dietrich, P Oberender, K Uberla, U Reitberger, C Schlegel, F Albers, S Ruckdäschel, R Welsch.   

Abstract

The present cost-of-illness study is focused on the costs of COPD in Germany. In a pre-study, data on 814 randomly selected patients were collected to achieve reliable figures for the distribution of COPD severity grades and the frequencies of exacerbations. The main study was performed on 321 randomly selected patients from the pre-study. Data on resource use were collected in a face-to-face interview with the respective physicians using the patient records as a basis. Costs associated with resource consumption were weighted with the frequencies of COPD severity grades as assessed in the pre-study to determine the costs of COPD. Annual COPD-related costs per patient were 3,027 from the societal perspective. Main cost components were hospitalisations (26 %), medication (23 %) and early retirement (17 %). Annual COPD-related costs from the perspective of the German health insurance system (GKV) were 1,944 euros per patient.

Entities:  

Mesh:

Year:  2004        PMID: 15597250     DOI: 10.1055/s-2004-830143

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  8 in total

1.  Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.

Authors:  Petra Menn; Norbert Weber; Rolf Holle
Journal:  Health Qual Life Outcomes       Date:  2010-04-15       Impact factor: 3.186

Review 2.  The global impact of non-communicable diseases on macro-economic productivity: a systematic review.

Authors:  Layal Chaker; Abby Falla; Sven J van der Lee; Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-04-03       Impact factor: 8.082

3.  Transition from in-hospital ventilation to home ventilation: process description and quality indicators.

Authors:  Marc Kastrup; Benjamin Tittmann; Tanja Sawatzki; Martin Gersch; Charlotte Vogt; Max Rosenthal; Simone Rosseau; Claudia Spies
Journal:  Ger Med Sci       Date:  2017-12-19

4.  Estimates of costs for modelling return on investment from smoking cessation interventions.

Authors:  Marta Trapero-Bertran; Reiner Leidl; Celia Muñoz; Puttarin Kulchaitanaroaj; Kathryn Coyle; Maximilian Präger; Judit Józwiak-Hagymásy; Kei Long Cheung; Mickael Hiligsmann; Subhash Pokhrel
Journal:  Addiction       Date:  2018-03-13       Impact factor: 6.526

5.  Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation.

Authors:  Kathryn Coyle; Doug Coyle; Adam Lester-George; Robert West; Bertalan Nemeth; Mickael Hiligsmann; Marta Trapero-Bertran; Reiner Leidl; Subhash Pokhrel
Journal:  Addiction       Date:  2017-09-14       Impact factor: 6.526

6.  Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.

Authors:  Florian Kirsch; Anja Schramm; Larissa Schwarzkopf; Johanna I Lutter; Boglárka Szentes; Manuel Huber; Reiner Leidl
Journal:  Respir Res       Date:  2019-10-10

7.  Effectiveness of a specialist palliative home care nurse-patient consultation followed by an interprofessional telephone case conference compared with usual care among patients with non-oncological palliative care needs: protocol for the multicentre KOPAL cluster-randomised controlled trial.

Authors:  Gabriella Marx; Tina Mallon; Nadine Janis Pohontsch; Franziska Schade; Judith Dams; Manuel Zimansky; Thomas Asendorf; Silke Böttcher; Christiane A Mueller; Michael Freitag; Eva Hummers; Hendrik van den Bussche; Ingmar Schäfer; Hans-Helmut König; Stephanie Stiel; Nils Schneider; Friedemann Nauck; Tim Friede; Martin Scherer
Journal:  BMJ Open       Date:  2022-07-25       Impact factor: 3.006

8.  A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.

Authors:  Petra Menn; Reiner Leidl; Rolf Holle
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.558

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.